Association of tissue inhibitor of metalloproteinase 2 with non-alcoholic fatty liver disease in metabolic syndrome

• Published in: Archives of physiology and biochemistry Vol. 125; no. 5; pp. 441 - 446
• Main Authors: Yasmeen, Saira, Khan, Unab, Khan, Ghulam Mustafa, Fatima, Syeda Sadia
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 20.10.2019
• Subjects: metabolic syndrome; metalloproteinase; NAFLD; Obesity; TIMP2; metabolic syndrome; TIMP2; Obesity; NAFLD; metalloproteinase
• ISSN: 1381-3455; 1744-4160
• DOI: 10.1080/13813455.2018.1481095

The aim of this case-control study was to assess TIMP2 level in subjects with or without metabolic syndrome (MetS) and to associate levels with non-alcoholic fatty liver changes (NAFLD). Thirty-three MetS subjects and 55 controls were recruited. Anthropometric data, lipid and glucose profile, TIMP2 and liver ultrasound was performed. High TIMP2 was seen in MetS group (145.28 ± 23.11 pg/ml) versus controls (19.06 ± 1.19 pg/ml; p < .001). Serum cholesterol, triglyceride, LDL-c and glucose levels were significantly higher in MetS subjects (p < .05). MetS individuals (72.72%) showed positive fatty liver changes versus 14.5% controls. Elevated TIMP2 positively correlated with waist circumference, body fat, blood glucose and NAFLD. Furthermore, every unit rise in waist circumference and TIMP2 and a unit decrease in HDL were associated with higher odds of developing NAFLD (p < .05). There may be concurrent relationship between TIMP2 and NAFLD in MetS that requires further evaluation to improve risk assessment and early diagnosis of MetS.